A new paradigm in cancer treatment – combining the effectiveness of targeted therapy and immunotherapy

A new paradigm in cancer treatment – combining the effectiveness of targeted therapy and immunotherapy

Archive - 2005

Collaboration with Sareum Holdings

Karus Therapeutics is pleased to announce it has entered into a collaborative agreement with AIM-listed Sareum Holdings plc, a specialist structure-based drug discovery and services business. Sareum will provide computational chemistry expertise to support Karus's therapeutic discovery programmes based on inhibitors of histone deacetylase (HDAC). Financial terms of the agreement were not disclosed.